title: Whipping NF-κB to Submission via GADD45 and MKK7.
abstract: NF-κB protects malignant cells from death and therefore it was considered as a cancer treatment target. However, systemic NF-κB inhibition resulted in inflammation and other undesired outcomes. In this issue of Cancer Cell, Tornatore and colleagues solve this problem by targeting the GADD45:MKK7 module mediating NF-κB-induced survival of multiple myelomas.
authors.affiliation: Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Moores Cancer Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA. Electronic address: karinoffice@ucsd.edu.
authors.forename: Michael
authors.initials: M
authors.lastname: Karin
mesh_terms: D000818:Animals; D018797:Cell Cycle Proteins / Q000378:metabolism*; D006801:Humans; D048688:MAP Kinase Kinase 7 / Q000378:metabolism*; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism*; D009687:Nuclear Proteins / Q000378:metabolism*; D000097642:GADD45 Proteins
chemical_list: D018797:Cell Cycle Proteins; D048688:MAP Kinase Kinase 7; D016328:NF-kappa B; D009687:Nuclear Proteins; C439070:GADD45A protein, human; D000097642:GADD45 Proteins; C482569:MAP2K7 protein, human